Key Insights• According to the research report, "Canada EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Canada EPA & DHA Market is anticipated to grow at more than 7.94% CAGR from 2026 to 2031. The Canadian EPA & DHA market is gradually expanding as the country faces an increasing burden of cardiovascular and chronic disease driven by population aging, a high prevalence of modifiable risk factors, and growing consumer adoption of natural health products. Canada's population reached approximately 41.7 million on July 1, 2025, with Statistics Canada estimating that people aged 65 and older accounted for 19.5% of the population and that residents aged 85 and older numbered 951,833. According to the Heart & Stroke Foundation's February 2026 report, more than 6 million people in Canada live with heart disease or stroke, a higher figure than previously estimated. Nine in 10 Canadians have at least one key modifiable risk factor, more than 8.2 million adults have been diagnosed with high blood pressure, more than one in four adults has high cholesterol, and more than 3.9 million Canadians live with diabetes, over three times the number in 2000. The growing clinical burden is placing additional pressure on Canada's healthcare system and consumer health sector to strengthen access to EPA and DHA through natural health products, prescription therapies, fortified foods, and infant nutrition.• Canada's EPA & DHA market is characterized by a well-developed natural health product (NHP) ecosystem comprising domestic supplement manufacturers, multinational consumer health brands, marine oil refiners, algal oil developers, pharmacy chains, and health food retailers. Nova Scotia is a historic center of omega-3 refining, hosting the Mulgrave facility that was transferred to KD Pharma Group in October 2024 as part of its acquisition of dsm-firmenich's Marine Lipids business, including the MEG-3 brand.

The province is also home to Mara Renewables, which raised USD 9.1 million from S2G Investments in July 2025 to scale its precision-fermented algal omega-3 platform, taking its total funding beyond USD 51 million. Leading domestic consumer brands such as Jamieson Wellness, which reported consolidated 2025 revenue of CAD 822.1 million, up 12.0% year-over-year, and Nature's Way Canada (NutraSea) are expanding their presence in both domestic and international markets.• Regulatory oversight for EPA and DHA products in Canada is administered by Health Canada through several distinct frameworks. Omega-3 supplements are regulated as natural health products under the Natural Health Products Regulations, requiring a product licence and Natural Product Number (NPN) before sale. Fortified foods are regulated under the Supplemented Foods provisions of the Food and Drug Regulations, prescription omega-3 drugs are regulated under the Food and Drug Regulations, and infant formula is subject to pre-market notification under Division 25. New NHP labelling requirements, including a mandatory bilingual Product Facts Table, came into force on June 21, 2025. The Canadian EPA & DHA market is largely supplied through imported refined oils and finished products from multinational manufacturers, complemented by domestic refining and encapsulation capacity, with distribution concentrated through pharmacy chains, grocery retailers, warehouse clubs, and e-commerce.Market Outlook• A defining characteristic of Canada's EPA & DHA market is the progressive modernization of the natural health product sector under a strengthened regulatory and labelling regime.

Manufacturers are reformulating and relabelling products to comply with the Product Facts Table requirements that took effect in June 2025, while legacy licensed products benefit from a further transition period of approximately three years. These changes are expected to improve consumer clarity on EPA and DHA dosing, warnings, and directions, while encouraging consolidation toward larger brands with the resources to absorb compliance costs. Simultaneously, prescription EPA is gaining traction in cardiovascular prevention. HLS Therapeutics reported that Vascepa revenue in Canada rose 9.1% to CAD 24.6 million in 2025, with unit volume increasing 23%, supported by expanded provincial access. In July 2025, Nova Scotia Pharmacare listed Vascepa on its formulary, and HLS reports that the product is now available to more than 95% of eligible Canadians covered by public plans or private insurance.• The market also reflects Canada's growing emphasis on preventive health through integrated care and self-care pathways. Public health messaging on cardiovascular risk, combined with pharmacist-led advice in community pharmacies, is increasing awareness of omega-3 supplementation for heart, brain, eye, and joint health.

The Supplemented Foods regulations, whose transition period ended on January 1, 2026, now require fortified foods and beverages containing added ingredients such as EPA and DHA to carry a standardized Supplemented Food Facts Table and caution identifier where applicable, providing a clearer pathway for omega-3-enhanced beverages and functional foods. In infant nutrition, Canada recorded 365,737 live births in 2024, up 3.7% from 352,644 in 2023, although the total fertility rate fell to a record low of 1.25 children per woman, which is encouraging infant formula manufacturers to focus on premium DHA-fortified formulations.Market DynamicsDriver: Rising cardiovascular disease burden and demographic aging supported by a strong natural health product cultureCanada's EPA & DHA market is primarily driven by the growing prevalence of cardiovascular and metabolic conditions associated with demographic aging and lifestyle-related risk factors. More than 6 million people in Canada live with heart disease or stroke, and nine in 10 Canadians have at least one key modifiable risk factor, according to the Heart & Stroke Foundation's February 2026 report. More than one in four adults has high cholesterol, and more than 3.9 million Canadians have diabetes. Nearly eight in 10 adults and youth eat fewer than five servings of fruits and vegetables per day, reflecting broader dietary gaps that include low consumption of oily fish. Canada's aging population, with seniors accounting for 19.5% of the population in 2025, is reinforcing demand for products that support cardiovascular, cognitive, and joint health.

Canadians have a long-standing familiarity with natural health products, and pharmacists play a central role in recommending omega-3 supplements. As public health programs continue promoting cardiovascular risk awareness, pharmacies and retailers are witnessing growing demand for high-quality EPA and DHA products with clear dosing and evidence-based claims.Challenge: Regulatory compliance costs and dependence on imported marine raw materialsOne of the principal challenges facing Canada's EPA & DHA market is the rising cost of regulatory compliance for natural health products and the country's dependence on imported marine raw materials. The new NHP labelling requirements, including the bilingual Product Facts Table, require extensive packaging redesign, translation, and in some cases fold-out or peel-back labels, which industry associations such as the Canadian Health Food Association have described as prohibitive for low-volume products, while proposed cost recovery fees for product evaluations and site licences continue to raise concerns about product rationalization among smaller manufacturers. Additionally, Canadian refiners and brands rely on imported crude fish oil from Peru, Chile, and other origins, exposing them to raw material volatility. Peru's first 2026 north-central anchovy quota was set at 1,914,049 tonnes, approximately 36% lower than in 2025, following a coastal El Niño event. Together, these factors contribute to cost pressures, potential product rationalization, and price volatility for omega-3 products.Trend: Expansion of algal omega-3 innovation and international growth of Canadian brandsCanada is experiencing a gradual shift toward sustainable, fermentation-based omega-3 production and the internationalization of domestic supplement brands.

Mara Renewables, based in Nova Scotia, is commercializing microalgal DHA oils, concentrates, softgels, and powders through its Algarithm and Humanative subsidiaries for dietary supplements, infant nutrition, food and beverage, and animal health applications, supported by its July 2025 financing round. Domestic brands are also leveraging Canada's reputation for quality to expand abroad, with Jamieson Wellness reporting that its China revenue grew more than 56% in 2025 and projecting 20% to 30% growth in China in 2026. The increasing adoption of e-commerce, pharmacy loyalty programs, and practitioner channels is expected to strengthen long-term consumer engagement, while the growing emphasis on sustainability and traceability is boosting demand for certified marine oils and algal alternatives. The Product Facts Table is also expected to accelerate the shift toward higher-dose, clearly labelled EPA and DHA formulations.Policies• Natural Health Products Regulations and Product Licensing: All omega-3 supplements containing EPA and DHA must obtain a product licence and Natural Product Number (NPN) from Health Canada's Natural and Non-prescription Health Products Directorate before they can be sold in Canada. Manufacturers, packagers, labellers, and importers must hold site licences and comply with Good Manufacturing Practices. Health Canada's fish oil monograph specifies permitted doses, sources, and recommended uses for EPA and DHA.• NHP Labelling Requirements and Product Facts Table: Amendments to the Natural Health Products Regulations came into force on June 21, 2025, requiring a standardized bilingual Product Facts Table covering medicinal ingredients, uses, warnings, directions, non-medicinal ingredients, and contact information, alongside plain-language and readability standards.

Products licensed under the former requirements benefit from an additional three-year transition period to conform.• Supplemented Foods Regulations: Foods and beverages containing added ingredients such as EPA and DHA are regulated under the Supplemented Foods provisions of the Food and Drug Regulations. Following the end of the transition period on January 1, 2026, these products must display a Supplemented Food Facts Table and, where applicable, a caution identifier, supporting a clearer regulatory pathway for omega-3-fortified functional foods.• Infant Formula Pre-market Notification: Infant formula is regulated under Division 25 of the Food and Drug Regulations, requiring manufacturers to notify Health Canada before selling a new or significantly changed formula. DHA and ARA are permitted optional ingredients, and most formulas marketed in Canada are fortified with DHA. Health Canada evaluates nutritional adequacy, safety, and manufacturing quality as part of the notification process.• Prescription Drug Approval and Provincial Reimbursement: Prescription omega-3 products such as icosapent ethyl are approved by Health Canada under the Food and Drug Regulations and reimbursed through provincial drug plans and private insurers following Canada's Drug Agency (formerly CADTH) assessment and pan-Canadian Pharmaceutical Alliance negotiations. Nova Scotia Pharmacare listed Vascepa for secondary cardiovascular prevention effective July 1, 2025.Segment AnalysisCanada EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Canada, particularly in infant formula, prenatal supplements, children's chewables, and cognitive and eye health products. DHA is added to most infant formulas marketed in Canada, and is increasingly sourced from algae for vegetarian and prenatal consumers.

Canadian algal developers such as Mara Renewables are focusing on DHA-rich microalgal oils for infant nutrition and supplements.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Canada, driven by increasing physician and pharmacist recommendation of high-purity EPA for cardiovascular risk reduction. HLS Therapeutics reported that Vascepa unit volume in Canada increased 23% in 2025, while revenue grew 9.1% to CAD 24.6 million. High-EPA concentrates are also gaining traction in mood support and sports nutrition supplements.Canada EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Canada due to its cost-effectiveness, established refining infrastructure in Nova Scotia, and broad consumer familiarity. KD Pharma Group's acquisition of dsm-firmenich's Marine Lipids business, completed in October 2024, includes the Mulgrave, Nova Scotia facility, reinforcing Canada's role in refined fish oil production for food, supplement, and pharmaceutical customers in North America.• Algae Oil maintains an important and growing position within Canada, particularly in infant nutrition, vegan supplements, and fortified foods. Mara Renewables' July 2025 financing supports the expansion of its precision fermentation platform and global manufacturing partnerships, while multinational suppliers provide algal DHA to formula and supplement manufacturers.• Krill Oil is a premium source category encompassing phospholipid-bound EPA and DHA from Antarctic krill, positioned for absorption and smaller capsule size. Krill supply has come under pressure following the early closure of the CCAMLR krill fishery on August 1, 2025, and again on August 12, 2026.• Other Marine Sources hold a niche position in the Canadian market, including cod liver oil, seal oil, salmon oil, and calamari oil, primarily used in traditional liquid supplements, children's products, and pet nutrition.Canada EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Canada, regulated as natural health products and distributed through pharmacies, grocery retailers, health food stores, and online platforms.

Supplement applications include softgels, liquids, chewables, and gummies targeting heart, brain, eye, joint, and prenatal health.• Pharmaceuticals represent a growing application segment, driven by prescription icosapent ethyl for secondary cardiovascular prevention. Vascepa is now available to more than 95% of eligible patients covered by public plans or private insurance, according to HLS Therapeutics.• Infant Formula represents a strategically important application segment, with DHA included in most formulas sold in Canada. Canada recorded 365,737 live births in 2024, up 3.7% from 2023, providing near-term volume support despite a record low total fertility rate of 1.25.• Food & Beverages encompasses omega-3-enriched eggs, milk, yogurt, juices, and functional beverages. The completion of the Supplemented Foods transition on January 1, 2026, provides a clearer regulatory pathway for omega-3-fortified products.• Clinical Nutrition & Medical Foods includes fish oil-based lipid emulsions for parenteral nutrition and enteral formulas used in hospitals and long-term care facilities, procured through provincial health authorities and group purchasing organizations.• Pet Nutrition represents the fastest-growing application segment in Canada, supported by high pet ownership and the premiumization of pet food and supplements. According to the Canadian Animal Health Institute's 2024 Canadian Pet Population Survey, published in March 2025, Canada is home to approximately 7.2 million dogs and 8.2 million cats, with pets present in more than half of Canadian households.Major EPA & DHA Manufacturers Operating in Canada• KD Pharma Group, dsm-firmenich, Jamieson Wellness, Nature's Way Canada (NutraSea), Sisu, Mara Renewables, Aker BioMarine, HLS Therapeutics, Abbott, Nestlé, and Reckitt (Mead Johnson) are leading players in the Canadian EPA & DHA market, offering refined fish oils, algal oils, krill oil, finished natural health products, prescription EPA, and DHA-fortified infant formula. KD Pharma Group completed its acquisition of dsm-firmenich's Marine Lipids business, including the Mulgrave facility, in October 2024.

Jamieson Wellness reported 2025 revenue of CAD 822.1 million, up 12.0%. Their strong presence, product licensing expertise, pharmacist education programs, and established relationships with retailers and healthcare professionals have driven adoption across the Canadian market.• The market is also supported by contract manufacturers, private-label suppliers, ingredient distributors, and third-party certification programs that provide formulation, encapsulation, and quality assurance support. With established refining capacity in Nova Scotia and an emerging algal fermentation sector, Canada remains an important contributor to North American omega-3 supply.Canada EPA & DHA Supply and Pricing Economics• EPA and DHA products in Canada represent value-added nutritional products whose pricing depends on source, concentration, chemical form, and regulatory compliance costs. Pricing varies considerably between standard fish oil, high-concentration oils, krill oil, algal oil, and prescription EPA.• Retail pricing of omega-3 supplements is influenced by imported crude oil costs, currency fluctuations between the Canadian and U.S. dollar, and the cost of complying with NHP labelling requirements. Refined fish oil prices normalized by late 2024 after the El Niño-related disruption, but the reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on raw material prices.• Prescription EPA is reimbursed through provincial drug plans and private insurance for eligible patients, while omega-3 supplements are typically paid out-of-pocket or through health spending accounts offered by employer benefit plans.• Infant formula pricing reflects premium DHA and ARA fortification, while pet nutrition products incorporating omega-3 command higher price points through veterinary and specialty pet retail channels.Market Outlook by Consumer Health Spending and Supply Infrastructure• Canada's EPA & DHA market growth is strongly linked to consumer health spending, demographic aging, and the strength of the natural health product sector, although regulatory compliance costs and raw material volatility remain significant factors influencing product availability and pricing.• Private consumer spending drives the supplement segment, while provincial drug plans and private insurers are expanding access to prescription EPA. Pharmacies, grocery chains, and e-commerce platforms continue to strengthen omega-3 visibility through private label ranges, loyalty programs, and pharmacist consultations.• The future growth opportunity for EPA and DHA in Canada depends on navigating the NHP labelling transition, expanding provincial reimbursement for prescription EPA, scaling domestic algal production, and growing exports of Canadian brands.

Greater integration of pharmacist-led cardiovascular risk counselling, digital health platforms, and functional food innovation under the Supplemented Foods framework will likely become key strategies for expanding category penetration across Canada.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.